IPSEY Overview
Upcoming Projects (IPSEY)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (IPSEY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (IPSEY)
-
Phase 3 data of ONIVYDE for first line pancreatic due 1H 2017
Tickers: IPSEY, MACK
Occurred on: Oct 11, 2016 -
European Commission Approves Exelixis' (EXEL) Cabometyx for Treatment of Adults With Advanced Renal Cell Carcinoma
Tickers: EXEL, IPSEY
Occurred on: Sep 14, 2016
Strategic Initiatives (IPSEY)
-
Ipsen (IPSEY) Completes Acquisition of Clementia Pharmaceuticals (CMTA)
Tickers: IPSEY, CMTA
Announcement Date: Apr 18, 2019 -
Ipsen (IPSEY) Agrees to Acquire Some of Merrimack's (MACK) Oncology Assets, Including Pancreatic Cancer Drug Onivyde, For Up to $1 Billion
Tickers: MACK, IPSEY
Announcement Date: Jan 09, 2017 -
Exelixis (EXEL) Transfers Canadian Cabometyx Rights to Ipsen (IPSEY), Retains Rights in U.S and Japan
Tickers: EXEL, IPSEY
Announcement Date: Dec 21, 2016
